WELLFISH TECH AND SALMON GROUP ENTER PARTNERSHIP

WellFish Tech and Salmon Group enter partnership to bring systematic fish health monitoring across Norwegian salmon and trout production. WellFish Tech has entered a commercial partnership with Salmon Group. Headquartered in Bergen, Salmon Group represents 40 owner companies and 62 food-producing companies along the Norwegian coast. Together, the network produces more than 220,000 tonnes of salmon and trout annually, equivalent to more than one billion meals each year. The agreement is the largest commercial contract in WellFish Tech’s history to date.

Under the partnership, WellFish Tech will work with Salmon Group and its owners’ companies to provide systematic blood biomarker analysis based on blood biochemistry across sites and companies within the network, generating fish health data that gives the group a consolidated overview of biological status across its production base. The data will serve both operational and regulatory purposes, supporting member companies’ fish health reporting as well as their own biological decision-making.

A central element of the partnership is the group-level view developed specifically for Salmon Group: a consolidated overview of fish health data across all owner companies in the network. Where individual companies today have visibility into their own biological status, the group view gives Salmon Group a complete picture of conditions across its entire production base at once.

The value of this becomes particularly clear where member companies share fjord systems. Consolidated biological data provides a shared factual basis for coordination between neighbouring sites, structured experience-sharing between companies and coordinated contingency and response plans for biological challenges such as sea lice or disease. This gives Salmon Group a collective resource that no individual member company would have access to on its own.

“We need solutions that actually tell us what is happening inside the fish, not just what we can observe from the outside,” says Jan Olav Langeland, CEO, Salmon Group. “Blood biochemistry gives us that. And when we can see the fish health status across sites and fjord systems, it opens up a completely different level of coordination and joint preparedness. That is what this agreement is about.”

“Bringing systematic blood biomarker monitoring to a network of this scale is a significant step, not just for WellFish Tech, but for what evidence-based fish health management can look like across the industry,” says Charlie Granfelt, CEO, WellFish Tech. “It shows that clinical biochemistry monitoring can scale from a single site to an entire network and that is exactly the direction we believe the industry is heading. We are looking forward to working with the central administration and the companies of Salmon Group.”

Image: Jan Olav Langeland, CEO Salmon Group and Charlie Granfelt, CEO WellFish Tech